Platelet factor 4 enhances generation of activated protein C in vitro and in vivo

Blood

Volumn 102, Issue 1, 2003, Pages 146-151

  Slungaard, Arne ^a   Fernandez, Jose A ^b   Griffin, John H ^b   Key, Nigel S ^b   Long, Janel R ^b   Piegors, Donald J ^b   Lentz, Steven R ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; RECOMBINANT THROMBOCYTE FACTOR 4; THROMBIN;

ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENDOTHELIUM CELL; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; MONKEY; MONOLAYER CULTURE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOSIS; UMBILICAL VEIN;

EID: 0037630133     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-11-3529     Document Type: Article

References (52)

1. Branson HE, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet. 1983;2:1165-1168.
2. Dreyfus M, Magny JF, Bridey F, et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med. 1991;325:565-568.
3. Dreyfus M, Masterson M, David M, et al. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost. 1995;21:371-381.
4. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989;264:4743-4746.
5. Isermann B, Hendrickson S, Zogg M, et al. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest. 2001;108:537-546.
6. Bourin M-C, Boffa M-C, Björk I, Lindahl U. Functional domains of rabbit thrombomodulin. Proc Natl Acad Sci U S A. 1986;83:5924-5928.
7. Lin J-H, McLean K, Morser J, et al. Modulation of glycosaminoglycan addition in naturally expressed and recombinant human thrombomodulin. J Biol Chem. 1994;269:25021-25030.
8. Bourin M-C, Lundgren-Akerlund E, Lindahl U. Isolation and characterization of the glycosaminoglycan component of rabbit thrombomodulin proteoglycan. J Biol Chem. 1990;265:15424-15431.
9. Preissner KT, Loyama T, Müller D, Tschopp J, Müller-Berghaus G. Domain structure of the endothelial cell receptor thrombomodulin as deduced from modulation of its anticoagulation functions: evidence for a glycosaminoglycan-dependent secondary binding site for thrombin. J Biol Chem. 1990;265:4915-4922.
10. Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function: a potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest. 1993;91:1721-1730.
11. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759-2779.
12. Wassom DL, Loegering DA, Solley GO, et al. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest. 1981;67:651-661.
13. Zucker MB, Katz IR. Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med. 1991;198:693-702.
14. Slungaard A, Key NS. Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity: a structure-function analysis. J Biol Chem. 1994;269:25549-25556.
15. Slungaard A, Decker TD, Dandelet LA, Key NS. Platelet factor 4 binds to GLA domain-containing clotting factors in human plasma and alters their activities: a potential new natural anticoagulant mechanism. Thromb Hemostas. 1997;78:644.
16. Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest. 1993;92:2003-2012.
17. Gibbs CS, Coutre SE, Tsiang M, et al. Conversion of thrombin into an anticoagulant by protein engineering. Nature. 1995;378:413-416.
18. Lentz SR, Fernández JA, Griffin JH, et al. Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system. Arterioscler Thromb Vasc Biol. 1999;19:1744-1750.
19. Myers JA, Gray GS, Peters DJ, et al. Expression and purification of active recombinant platelet factor 4 from a cleavable fusion protein. Protein Expr Purif. 1991;2:136-143.
20. Maione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor 4 and related peptides. Science. 1990;247:77-79.
21. Heeb MJ, Schwarz HP, White T, Lämmie B, Berrettini M, Griffin JH. Immunoblotting studies of the molecular forms of protein C in plasma. Thromb Res. 1988;52:33-43.
22. Gupta K, Ramakrishnan S, Browne PV, Solovey A, Hebbel RP. A novel technique for culture of human dermal microvascular endothelial cells under either serum-free or serum-supplemented conditions: isolation by panning and stimulation with vascular endothelial growth factor. Exp Cell Res. 1997;230:244-251.
23. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000;105: 71-77.
24. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood. 1992;79:2340-2348.
25. Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation. 1995;91:2188-2194.
26. Holt JC, Niewiarowski S. Biochemistry of α granule proteins. Semin Hematol. 1985;22:151-163.
27. Rollins BJ. Chemokines. Blood. 1997;90:909-928.
28. Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc Natl Acad Sci U S A. 1993;90:3574-3577.
29. Daly TJ, LaRosa GJ, Dolich S, Maione TE, Cooper S, Broxmeyer HE. High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin 8 and platelet factor 4. J Biol Chem. 1995;270:23282-23292.
30. Gewirtz AM, Zhang J, Ratajczak J, et al. Chemokine regulation of human megakaryocytopoiesis. Blood. 1995;86:2559-2567.
31. Broxmeyer HE, Sherry B, Cooper S, et al. Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells: interacting effects involving suppression, synergistic suppression, and blocking of suppression. J Immunol. 1993;150:3448-3458.
32. Petersen F, Bock L, Flad HD, et al. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. Immunol. 1998;161:4347-4355.
33. Petersen F, Ludwig A, Flad HD, Brandt E. TNF-alpha renders human neutrophils responsive to platelet factor 4. Comparison of PF-4 and IL-8 reveals different activity profiles of the two chemokines. J Immunol. 1996;156:1954-1962.
34. Fleischer J, Grage-Griebenow E, Kasper B, et al. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol. 2002;169:770-777.
35. Goldberg ID, Stemerman MB, Handin RI. Vascular permeation of platelet factor 4 after endothelial injury. Science. 1980;209:611-612.
36. Dudek AZ, Pennell CA, Decker TD, et al. Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C: potential anticoagulant role in coagulation. J Biol Chem. 1997;272:31785-31792.
37. Parkinson JF, Garcia JG, Bang NU. Decreased thrombin affinity of cell-surface thrombomodulin following treatment of cultured endothelial cells with beta-D-xyloside. Biochem Biophys Res Commun. 1990;169:177-183.
38. Slungaard A, McLean K. The glycosaminoglycan (GAG) status of cell-associated thrombomodulin regulates its thrombin affinity [abstract]. Blood. 1996;86:286a.
39. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A. 1996;93:10212-10216.
40. Laszik Z, Mitro A, Taylor FB Jr, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation. 1997;96:3633-3640.
41. Taylor FB Jr, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood. 2001;97:1685-1688.
42. Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest. 1984;74:341-350.
43. Dählback B. Procoagulant and anticoagulant properties of coagulation factor V: factor V Leiden (APC resistance) causes hypercoagulability by duel mechanisms. J Lab Clin Med. 1999;133:415-422.
44. Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest. 1981;68:1221-1228.
45. Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci U S A. 1985;82:1121-1125.
46. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood. 1986;68:1218-1223.
47. de Fouw NJ, van Hinsbergh VW, de Jong YF, Haverkate F, Bertina RM. The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Haemost. 1987;57:176-182.
48. de Fouw NJ, de Jong YF, Haverkate F, Bertina RM. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor - no evidence for a cofactor role of protein S. Thromb Haemost. 1988;60:328-333.
49. Rezaie AI. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem. 2001;276:15567-15570.
50. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med. 2002;196:561-564.
51. Joyce DE, Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med. 2002;30:S288-S293.
52. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344:699-709.